GLP-1 analogues: a new therapeutic approach to prevent ductopenia in cholangiopathies?

Beuers, U.; Göke, B.

DOI
10.1136/gut.2008.165688

Publication date
2009

Document Version
Final published version

Published in
Gut

Citation for published version (APA):
GLP-1 analogues: a new therapeutic approach to prevent ductopenia in cholangiopathies?

Ulrich Beuers and Burkhard Göke

*Gut* 2009 58: 902-903
doi: 10.1136/gut.2008.165688

Updated information and services can be found at:
http://gut.bmj.com/content/58/7/902.full.html

These include:

**References**
This article cites 13 articles, 4 of which can be accessed free at:
http://gut.bmj.com/content/58/7/902.full.html#ref-list-1

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

To order reprints of this article go to:
http://gut.bmj.com/cgi/reprintform

To subscribe to *Gut* go to:
http://gut.bmj.com/subscriptions
GLP-1 analogues: a new therapeutic approach to prevent ductopenia in cholangiopathies?  

Ulrich Beuers,1 Burkhard Göke2

Incretins have attracted the attention of the medical community for a century. They are secreted from the gastrointestinal tract into the splanchnic circulation in response to nutrient ingestion and enhance glucose-stimulated insulin secretion. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are the two incretins identified in animals and man. They are secreted from the gastrointestinal tract and various regions of the central nervous system are mediated via a specific GLP-1 receptor (GLP-1R). In pancreatic β cells, GLP-1 stimulates insulin biosynthesis and secretion via receptor-mediated activation of the β-cell-secreted pathway. GLP-1 also enhances β-cell proliferation and stimulates β-cell apoptosis and angiogenesis. Incretins have attracted particular attention since their role in the pathogenesis of diabetes mellitus. The recent identification of both GLP-1R and DPP-4 inhibitors and their ability to secrete different growth factors, such as neural growth factor, epidermal growth factor, and vascular endothelial growth factor, has set the stage for the development of incretin-based therapies. The use of incretins to prevent ductopenia in cholangiopathies is an attractive therapeutic strategy to treat chronic liver disease in adults and children which slowly progress to cirrhosis and liver failure. Among these, primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are the most frequent adult diseases, leading to death after about 10–15 years without adequate treatment. Chronic cholangiopathies are characterised by increasing transdifferentiation of proliferating cholangiocytes towards a neuroendocrine phenotype. Finally, an imbalance occurs between enhanced cholangiocyte death via apoptosis that prevails over adaptive cholangiocyte proliferation resulting in ductopenia. The proliferative response of cholangiocytes as a key repair mechanism of the liver in various types of liver injury—arising from proliferation of pre-existing bile ductular cells, but also from differentiated progenitor cells—and their central role in fibrogenesis are apparently linked to their transdifferentiation into neuroendocrine cells and, thereby, their ability to secrete different growth factors, neuropeptides, hormones and cytokines, in order to communicate in a paracrine fashion with neighbouring cholangiocytes and other liver cells. The proliferative response is, thereby, mediated by neuropeptides, such as neural growth factor (NGF), dopamine, acetylcholine, epinephrine and calcitonin gene-related peptide (CGRP), or neuroendocrine hormones, such as growth hormone (GH)/epinephrine and calcitonin gene-related peptide (CGRP), or neuroendocrine hormones, such as growth hormone (GH)/

insulin-like growth factor (IGF) 1, oestrogens, prolactin and GLP-1. In the present issue of Gut, Marzioni et al (see page 990) further characterised the potential role of GLP-1 in the polyphonic cholangiocyte response to cholestatic injury. They show in an elegant series of experiments that the stable GLP-1 agonist, exendin-4, prevents glycochenodeoxycholic acid (GCDDCA)-induced Bax mitochondrial translocation, cytochrome c release and caspase 3 activation (in other words: bile acid-induced apoptosis) in rat cholangiocytes in vitro via a PI3K-dependent mechanism. Furthermore, exendin-4 prevents cholangiocyte apoptosis and bile duct loss in bile duct-ligated rats exposed in vivo to CCl4, an experimental model of ductopenic cholangiopathies. The authors, thereby, substantiate their formulation of ductopenic cholangiopathies. They hypothesise that GLP-1 analogues might be effective in slowing down ductopenic cholangiopathies. Still, this is the first rodent in vivo model of short-term injury in which an antiapoptotic and protective effect of GLP-1 has been demonstrated. This in vivo model also does not exactly reflect the liver involvement in ductopenic disorders in humans. Therefore, confirmation of these promising effects of GLP-1 in additional experimental models including one mimicking advanced chronic cholestasis is warranted. Adverse effects of GLP-1 analogues such as nausea and vomiting may hinder some patients with cholestatic disorders from obtaining long-term treatment, whereas hypoglycaemia due to GLP-1 monotherapy is mostly not observed. A number of other concerns need to be addressed before GLP-1 analogues can be considered for clinical evaluation in patients with cholestatic ductopenic disorders such as PBC or PSC.

Ursodeoxycholic acid (UDCA) is the standard treatment for PBC. Up to two-thirds of patients show an adequate response towards UDCA with a good long-term prognosis not requiring additional medical treatment. Taurine-conjugated UDCA (TUDCA) has potent anticholestatic and antiapoptotic properties. Like exendin-4 in cholangiocytes, TUDCA has been shown to antagonise GCDDCA-induced apoptosis in hepatocytes by inhibiting Bax mitochondrial translocation, mitochondrial cytochrome c release and caspase 3 activation in a PI3K-dependent fashion. The protective action of TUDCA on cholangiocytes like that on hepatocytes in experimental cholestasis is mediated in part by Ca2+/cPKCa-dependent mechanisms, and GLP-1, like TUDCA in cholestatic hepatocytes, stimulates pancreatic β cell secretion via Ca2+-dependent mechanisms. Considering these potential similarities in the mechanisms of action of GLP-1 and TUDCA at the cellular level, one might doubt that just the one-third of patients with PBC who do not respond adequately to UDCA treatment and are in need of alternative/additive treatment options might adequately respond to GLP-1 analogues. For these patients, treatment strategies with mechanisms of action clearly different from UDCA conjugates might be advantageous. Therefore, it appears crucial to demonstrate an additive antiapoptotic and cytoprotective effect on cholangiocytes of GLP-1 analogues beyond that of UDCA amides in experimental cholestasis before clinical studies are designed.

Patients with other inflammatory biliary diseases such as PSC and, to some degree in adults, cystic fibrosis-associated liver disease carry a risk of developing cholangiocarcinoma during the long-term course of their disease. GLP-1 analogues exert not only antiapoptotic, but also proliferative effects on pancreatic β cells. An antiapoptotic and proliferative treatment strategy might be potentially harmful in a disease with a lifetime risk of 10–15% of developing cholangiocarcinoma like PSC. Thus, GLP-1 does not appear attractive as a long-term treatment in these disorders.

In summary, the authors are to be congratulated for this innovative study and their extensive previous work in this field which has unravelled a fascinating cross-talk between the liver, bile ducts and the gut. Still, it may become difficult to identify the patient population which might possibly benefit from treatment with GLP-1 analogues. The authors know best that there remains a long way to go.

Competing interests: None.


REFERENCES